Related Experiment Videos
A guide to health measurement.
Dianne Jackowski1, Gordon Guyatt
1Department of Clinical Epidemiology and Biostatistics, Health Science Centre Room 2C12, McMaster University, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada. jackowdm@mcmaster.ca
Clinical Orthopaedics and Related Research
|August 5, 2003
Summary
Evaluating new therapies requires assessing health-related quality of life (HRQoL) impact. Valid measurement instruments and study designs are crucial for reliable HRQoL outcomes in clinical research.
Area of Science:
- Clinical research methodology
- Health economics
- Patient-reported outcomes
Background:
- Healthcare systems increasingly demand evidence of treatment benefits, including impact on patient health-related quality of life (HRQoL).
- HRQoL assessment is vital for marketing and reimbursement decisions for new therapies.
- Adequate evidence encompasses physical, mental, and emotional health impacts.
Purpose of the Study:
- To provide guidelines for measuring HRQoL as an outcome in clinical research.
- To assist clinicians and investigators in selecting appropriate HRQoL measurement instruments and study designs.
- To ensure the validity and reliability of HRQoL data in evaluating therapeutic interventions.
Main Methods:
- Discussion of general health and utility measures for broad applicability.
- Explanation of specific measures for targeted health aspects related to diseases or functions.
- Emphasis on the importance of instrument validity and responsiveness to change.
Main Results:
- Two main categories of HRQoL measures exist: general and specific.
- The choice of measurement instrument must be appropriate for the research question.
- Study design must ensure valid and interpretable HRQoL results.
Conclusions:
- Valid and reliable measurement of HRQoL is essential for evaluating treatment effectiveness.
- Investigators must carefully select HRQoL instruments and design studies to yield meaningful data.
- These guidelines support informed decision-making regarding new therapies in clinical practice and health policy.